<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943721</url>
  </required_header>
  <id_info>
    <org_study_id>ForSight VISION5 Study 504</org_study_id>
    <nct_id>NCT01943721</nct_id>
  </id_info>
  <brief_title>A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ForSight Vision5, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ForSight Vision5, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Phase 1 study is to evaluate the VISION5 Product's safety and efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Tonometry (change from baseline)</measure>
    <time_frame>Week 2, 6, 12 and Months 4,5,6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by Slit Lamp Exam</measure>
    <time_frame>Weeks 2,6,12 and Months 4,5,6</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>VISION5 Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VISION5 Product in both eyes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VISION5 Product</intervention_name>
    <arm_group_label>VISION5 Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Primary open-angle glaucoma or ocular hypertension in both eyes

          -  Best-corrected distance vision of 20/100 or better

          -  Stable visual field

        Exclusion Criteria:

          -  Cup-to-disc ratio greater than 0.8

          -  Laser surgery for glaucoma/ocular hypertension on one or both eyes within the last 12
             months

          -  Corneal refractive surgery within prior 6 months

          -  Past history of any incisional surgery for glaucoma at any time

          -  Corneal abnormalities that would interfere with tonometry readings

          -  Current participation in an investigational drug or device study or participation in
             such a study within 30 days of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Rubin</last_name>
    <role>Study Director</role>
    <affiliation>ForSight VISION5</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact ForSight VISION5 for Trial Locations</name>
      <address>
        <city>Contact ForSight VISION5 for Trial Locations</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Latvia</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2013</study_first_submitted>
  <study_first_submitted_qc>September 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

